Denver Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Denver Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-45,383	Closed	-$4.2M	–	469
2016 Q3	$4.2M	Buy	45,383 +11,573	+34%	+$1.09M	0.18%	128
2016 Q2	$2.63M	Hold	33,810	–	–	0.12%	177
2016 Q1	$2.79M	Sell	33,810 -1,550	-4%	-$126K	0.12%	178
2015 Q4	$3.7M	Buy	35,360 +1,125	+3%	+$117K	0.17%	155
2015 Q3	$3.61M	Buy	34,235 +815	+2%	+$109K	0.16%	157
2015 Q2	$4.57M	Buy	33,420 +23,720	+245%	+$2.94M	0.17%	138
2015 Q1	$1.21M	Buy	+9,700	New	+$1.03M	0.04%	339

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Denver Investment Advisors's BMRN Position: Q4 2016 in Review

Denver Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 45,383 shares — an estimated $4.2M sold.

Denver Investment Advisors first reported a position in BMRN in Q1 2015 and held it in 7 quarters. The position peaked at $4.57M in Q2 2015. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

Denver Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Denver Investment Advisors sold 45,383 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $4.2M.
Denver Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 7 quarters.
Denver Investment Advisors's BioMarin Pharmaceuticals position peaked at $4.57M in Q2 2015.
415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Denver Investment Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.